Floatz logo

Oxybutynin

Cognitive Disorder

University of AlbertaSmall moleculePhase 4 / ApprovedDormant
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
89/ 100

Competitive context

132 Active assets in the Cognitive Disorder cohort.

Asset / SponsorPhaseRating
Nicotine
University of Southern California
Phase 2BBB
Metformin
Fudan University
Phase 4BB
Levodopa
Vanderbilt University Medical Center
Phase 4BB
QUETIAPINE
Emory University
Phase 4BB
Rivastigmine
VA Office of Research and Development
Phase 4BB

View all 50 →

Same molecule, other indications

Oxybutynin is also rated in:

urinary bladder, atony ofDormant
BB
Indicative · Phase 4
69 / 100
View asset →
ductal breast carcinoma in situDormant
BB
Indicative · Phase 3
64 / 100
View asset →
lobular breast carcinoma in situDormant
BB
Indicative · Phase 3
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →